Targeted prostate biopsy: Value of multiparametric magnetic resonance imaging in detection of localized cancer

Asian Journal of Andrology

Volumn 16, Issue 4, 2014, Pages 522-529

  Le, Jesse D ^a   Huang, Jiaoti ^a   Marks, Leonard S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fusion biopsy; magnetic resonance imaging (MRI); prostate biopsy; prostate cancer; targeted biopsy; ultrasound

Indexed keywords

ANALYTIC METHOD; ARTEMIS DEVICE; BIOPSY TECHNIQUE; CANCER DIAGNOSIS; CANCER LOCALIZATION; COGNITIVE FUSION BIOPSY; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED; HUMAN; MEDICAL DEVICE; MOLECULAR EVOLUTION; MULTICENTER STUDY (TOPIC); MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; URONAV DEVICE;

EID: 84904734596     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.122864     Document Type: Review

References (85)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. In: Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr; 2013. [Last accessed on 11 Feb 2014].
2. Silletti JP, Gordon GJ, Bueno R, Jaklitsch M, Loughlin KR. Prostate biopsy: past, present, and future. Urology 2007; 69: 413-6.
3. Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989; 142: 66-70.
4. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-5.
5. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW. Observations on pathology trends in 62, 537 prostate biopsies obtained from urology private practices in the United States. Urology 1998; 51: 186-95.
6. De Angelis G, Rittenhouse HG, Mikolajczyk SD, Shamel LB, Semjonow A. Twenty years of PSA: from Prostate Antigen to Tumor Marker. Rev Urol 2007; 9: 113-23.
7. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005; 23: 8146-51.
8. O'Dowd GJ, Miller MC, Orozco R, Veltri RW. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 2000; 55: 553-9.
9. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202.
10. Chon CH, Lai FC, McNeal JE, Presti JC. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 2002; 167: 2457-60.
11. Presti JC, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: 163-6.
12. Presti JC, O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003; 169: 125-9.
13. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152-7.
14. Presti JC. Prostate biopsy strategies. Nature clinical practice. Urology 2007; 4: 505-11.
15. Presti JC. Repeat prostate biopsy-when, where, and how. Urol Oncol 2009; 27: 312-4.
16. Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, et al. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol 2004; 171: 1850-4.
17. Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 2010; 13: 71-7.
18. Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007; 99: 1395-400.
19. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151: 1571-4.
20. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001; 166: 1679-83.
21. Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86-91.
22. Ashley RA, Inman BA, Routh JC, Mynderse LA, Gettman MT, et al. Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol 2008; 53: 976-83.
23. Fleshner N, Klotz L. Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology 2002; 60: 93-7.
24. Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, et al. Difference of cancer core distribution between first and repeat biopsy: in patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 2004; 58: 76-81.
25. Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, et al. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology 2005; 65: 735-9.
26. Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol 2011; 186: 850-4.
27. Loeb S, Schaeffer EM, Epstein JI. The Vanishing Prostate Cancer Phenomenon. Urology 2010; 76: 605-7.
28. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 1990; 323: 621-6.
29. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 46-66.
30. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, et al. Prostate Cancer: value of multiparametric MR imaging at 3 t for detection-histopathologic correlation. Radiology 2010; 255: 89-99.
31. Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, et al. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with gleason grade after radical prostatectomy. Radiology 2007; 246: 168-76.
32. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006; 50: 1163-75.
33. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenology 2004; 183: 1079-83.
34. Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-92.
35. Turnbull LW, Buckley DL, Turnbull LS, Liney GP, Knowles AJ. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. J Magn Reson Imaging 1999; 9: 311-6.
36. Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004; 14: 309-17.
37. Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009; 74: 1094-9.
38. Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009; 103: 883-8.
39. Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-95.
40. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and gleason grade in peripheral zone prostate cancer. Radiology 2011: 453-61.
41. Fütterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007; 17: 1055-65.
42. Park BK, Kim B, Kim CK, Lee HM, Kwon GY. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr 2007; 31: 534-8.
43. Scheenen TW, Klomp DW, Röll SA, Fütterer JJ, Barentsz JO, et al. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 2004; 52: 80-8.
44. Natarajan S, Marks LS, Margolis DJ, Huang J, Macairan ML, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol 2011; 29: 334-42.
45. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, et al. Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging 2013; 37: 48-58.
46. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-57.
47. Schimmöller L, Quentin M, Arsov C, Lanzman RS, Hiester A, et al. Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol 2013; 23: 3185-90.
48. Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013; 63: 125-40.
49. Engelhard K, Hollenbach HP, Kiefer B, Winkel A, Goeb K, et al. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol 2006; 16: 1237-43.
50. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183: 520-8.
51. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, et al. Areas suspicious for prostate cancer: mr-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259: 162-72.
52. Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, de Kaa CA, et al. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012: 1-8.
53. Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012; 30: 213-8.
54. Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010; 16: 1875-83.
55. Labanaris AP, Engelhard K, Zugor V, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 2010; 13: 65-70.
56. Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Intl 2011; 108: E171-8.
57. Rastinehad AR, Baccala J, Angelo A, Chung PH, Proano JM, et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol 2011; 185: 815-20.
58. Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, et al. multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012; 188: 2152-7.
59. Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol 2012; 189: 86-91.
60. Sonn GA, Chang E, Natarajan S, et al: Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol 2013. doi: 10.1016/j.eururo.2013. 03.025. [In press].
61. Miyagawa T, Ishikawa S, Kimura T, Suetomi T, Tsutsumi M, et al. Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol 2010; 17: 855-60.
62. Fiard G, Hohn N, Descotes JL, Rambeaud JJ, Troccaz J, et al. Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial Clinical Experience With Real-time 3-Dimensional Transrectal Ultrasound Guidance and Magnetic Resonance/Transrectal Ultrasound Image Fusion. Urology 2013: 1372-8.
63. Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011; 186: 2214-20.
64. Pondman KM, Futterer JJ, ten Haken B, Schultze Kool LJ, Witjes JA, et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol 2008; 54: 517-27.
65. Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol 2013; 23: 43-50.
66. Pinto PA, Chung PH, Rastinehad AR, Baccala J, Angelo A, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186: 1281-5.
67. Wright JL, Ellis WJ. Improved prostate cancer detection with anterior apical prostate biopsies. Urol Oncol 2006; 24: 492-5.
68. Jones JS, Zippe CD. Rectal sensation test helps avoid pain of apical prostate biopsy. J Urol 2003; 170: 2316-8.
69. Moussa AS, Meshref A, Schoenfield L, Masoud A, Abdel-Rahman S, et al. Importance of additional extreme anterior apical needle biopsies in the initial detection of prostate cancer. Urology 2010; 75: 1034-9.
70. Nix JW, Turkbey B, Hoang A, Volkin D, Yerram N, et al. Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. BJU Int 2012; 110: E694-700.
71. Haffner J, Potiron E, Bouyé S, Puech P, Leroy X, et al. Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. Prostate 2009; 69: 276-82.
72. Bott SR, Young MP, Kellett MJ, Parkinson MC. Anterior prostate cancer: is it more difficult to diagnose? BJU Int 2002; 89: 886-9.
73. Koppie TM, Bianco FJ Jr, Kuroiwa K, Reuter VE, Guillonneau B, et al. The clinical features of anterior prostate cancers. BJU Int 2006; 98: 1167-71.
74. Al-Ahmadie HA, Tickoo SK, Olgac S, Gopalan A, Scardino PT, et al. Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy. Am J Surg Pathol 2008; 32: 229-35.
75. Ouzzane A, Puech P, Lemaitre L, Leroy X, Nevoux P, et al. Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. Urology 2011; 78: 1356-62.
76. Lawrentschuk N, Haider MA, Daljeet N, Evans A, Toi A, et al. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Intl 2010; 105: 1231-6.
77. Tiwari P, Viswanath S, Kurhanewicz J, Sridhar A, Madabhushi A. Multimodal wavelet embedding representation for data combination (MaWERiC): integrating magnetic resonance imaging and spectroscopy for prostate cancer detection. NMR Biomed 2012; 25: 607-19.
78. Vos PC, Barentsz JO, Karssemeijer N, Huisman HJ. Automatic computer-aided detection of prostate cancer based on multiparametric magnetic resonance image analysis. Phys Med Biol 2012; 57: 1527-42.
79. Shah V, Turkbey B, Mani H, Pang Y, Pohida T, et al. Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. Med Phys 2012; 39: 4093-103.
80. Viswanath SE, Bloch NB, Chappelow JC, Toth R, Rofsky NM, et al. Central gland and peripheral zone prostate tumors have significantly different quantitative imaging signatures on 3 Tesla endorectal, in vivo T2-weighted MR imagery. J Magn Reson Imaging 2012; 36: 213-24.
81. Dall'Era MA. The economics of active surveillance for prostate cancer. Curr Opin Urol 2013; 23: 278-82.
82. Turkbey B, Mani H, Aras O, Ho J, Hoang A, et al. Prostate Cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013; 268: 144-52.
83. Mullins JK, Bonekamp D, Landis P, Begum H, Partin AW, et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int 2013; 111: 1037-45.
84. Park BK, Park JW, Park SY, Kim CK, Lee HM, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol 2011; 197: W876-81.
85. Mowatt G, Scotland G, Boachie C, Cruickshank M, Ford JA, et al. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technol Assess (Winchester, England) 2013; 17: vii-xix-1-281.